Table 4.

Effects of erlotinib and/or naproxen in the prevention of bladder cancer when agents were started 3 months after final OH-BBN treatment.

Urinary bladder cancers
GroupNumber of ratsCarcinogenTreatmentIncidenceMultiplicityWeight (mg)Number greater than 200 mg
125OH-BBNErlotinib, 42 mg/kg BW, 1×/week84% (5%↓)1.88 (31%↓)c490 (33%↓)d58% (29%↓)d
225OH-BBNNaproxen, 30 mg/kg BW/day (3 weeks on / 3 weeks off)84% (5%↓)2.68 (1%↓)d234 (68%↓)b,d44% (46%↓)a,d
325OH-BBNErlotinib + Naproxen (as indicated for groups 1 and 2)52% (41%↓)b0.96 (65%↓)b138 (81%↓)b8% (90%↓)b
424OH-BBNNone88%2.7173282%
  • Note: Female Fischer-344 rats received OH-BBN for 8 weeks beginning at 56 days of age. Administration of Erlotinib and/or Naproxen initiated three months after final OH-BBN treatment. Study terminated 11 months after the initial OH-BBN treatment. Numbers in parentheses represent percent decrease from the control group (group 4).

  • aStatistically significant from the control group (group 4) at P ≤ 0.05.

  • bStatistically significant from the control group (group 4) at P ≤ 0.01.

  • cStatistically significant from group 3 (P = 0.0458)

  • dStatistically significant from the combination group (group 3) at P ≤ 0.01.